EICHORPublic-registry site landscape for NCT04028492, “Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis”, a Idiopathic Gastroparesis study sponsored by Vanda Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04028492 (registry record) |
| Study title | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis |
| Official title | VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis |
| Sponsor | Vanda Pharmaceuticals |
| Condition(s) | Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis |
| Phase | PHASE3 |
| Listed sites | 36 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04028492.
Eichor generates a preliminary site-risk snapshot for NCT04028492 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
